Adjuvant therapy after nephrectomy for renal cell carcinoma

Area of Science:

• Oncology
• Nephrology
• Pharmacology

Background:

• Adjuvant therapy for renal cell carcinoma (RCC) post-nephrectomy aims to prevent recurrence.
• Vascular Endothelial Growth Factor Receptor (VEGFR) tyrosine kinase inhibitors (TKIs) are a class of drugs investigated for this purpose.
• Clinical trials like S-TRAC, ASSURE, and PROTECT have evaluated VEGFR TKIs in the adjuvant setting for RCC.

Purpose of the Study:

• To review and compare three major clinical trials (S-TRAC, ASSURE, PROTECT) investigating adjuvant VEGFR TKI therapy in renal cell carcinoma.
• To explore potential reasons for the differing outcomes observed across these trials, particularly the positive results of S-TRAC.

Main Methods:

• Comparative analysis of trial designs, patient populations, and treatment regimens of S-TRAC, ASSURE, and PROTECT.
• Review of primary endpoints, specifically disease-free survival (DFS).
• Formulation of hypotheses to explain the discrepancy in trial results.

Main Results:

• The S-TRAC trial showed a statistically significant improvement in DFS with sunitinib compared to placebo.
• The ASSURE and PROTECT trials did not demonstrate a significant benefit in DFS for patients treated with sunitinib, sorafenib, or pazopanib.
• Key differences in trial methodologies may contribute to the divergent outcomes.

Conclusions:

• Adjuvant VEGFR TKI therapy in renal cell carcinoma shows inconsistent efficacy across different clinical trials.
• The positive outcome in S-TRAC suggests sunitinib may have a role, but further investigation is needed to understand the factors contributing to its success and the failures in ASSURE and PROTECT.